Incobotulinum Toxin A ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
6	Parkinson disease	2
13	Multiple sclerosis/Neuromyelitis optica	1

2. Amyotrophic lateral sclerosis

Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01565395 (ClinicalTrials.gov)	March 2012	26/3/2012	Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Parkinson Disease;Amyotrophic Lateral Sclerosis	Drug: Incobotulinum Toxin A;Drug: placebo	Beth Israel Deaconess Medical Center	Merz Pharmaceuticals	Withdrawn	20 Years	80 Years	All	0	Phase 2	United States

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01653132 (ClinicalTrials.gov)	March 2012	25/7/2012	Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism	Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism	Sialorrhea	Drug: Incobotulinum Toxin A;Drug: Placebo	Beth Israel Deaconess Medical Center	NULL	Completed	18 Years	90 Years	All	10	Phase 2	United States
2	NCT01565395 (ClinicalTrials.gov)	March 2012	26/3/2012	Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Parkinson Disease;Amyotrophic Lateral Sclerosis	Drug: Incobotulinum Toxin A;Drug: placebo	Beth Israel Deaconess Medical Center	Merz Pharmaceuticals	Withdrawn	20 Years	80 Years	All	0	Phase 2	United States

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04265092 (ClinicalTrials.gov)	January 2014	22/10/2019	Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis	Gaitox :Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis an Observational Study on Gait Spatiotemporal Parameters	Multiple Sclerosis	Drug: Incobotulinum toxin A	Pôle Saint Hélier	NULL	Completed	18 Years	N/A	All	22		NULL